Exscientia Closes $100M in Series C Financing

Exscientia, a clinical-stage pharmatech company based in Oxford, England, raised $100 million in Series C funding. BlackRock, Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital participated in the round. Exscientia plans to use the funds to further develop its platform for autonomous drug design, expand its proprietary pipeline into clinical trials, and enhance its biological analytics capabilities. Exscientia has built AI systems that learn from a vast range of data and reapply enhanced knowledge through iterative design.

Exscientia Raises $100 Million in Series C Funding Led by BlackRock

Exscientia is an Oxford, England, UK-based clinical stage pharmatech pioneering the use of artificial intelligence (AI) to design new drugs. Led by Andrew Hopkins, CEO, Exscientia is an Artificial Intelligence (AI)-driven pharmatech company committed to discovering and designing medicines progressing AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform the how drugs are created. In addition to its growing proprietary pipeline, the company has conducted drug discovery partnerships with Bristol-Myers Squibb, Sanofi, Bayer and Dainippon Sumitomo as well as several biotech companies.

Exscientia is an AI-driven pharmatech company committed to discovering and designing medicines progressing AI-designed small molecules into the clinical setting and repeatedly demonstrate the ability of AI to transform the how drugs are created.

4 years ago

Exscientia Raises $100 Million in Series C Funding Led by BlackRock

ProblemTechnology

Solution

Covered on